Investors' speedy study hopes quashed as Novo Nordisk continues cardiovascular trial
A Sydbank analyst identifies one possible reason why Novo Nordisk dropped 9% on Wednesday, as some might have been surprised that more evidence is needed to back up Wegovy’s cardiovascular benefits.
by marketwire, translated by daniel pedersen
Novo Nordisk has decided to keep a large-scale study investigating the cardiovascular benefits of obesity drug Wegovy (semaglutide) running, which could be to the chagrin of investors who hoped for results sooner rather than later.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
